Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 9647–9649.

https://doi.org/10.1182/blood-2022-164444

Published: 2022

Journal Articles

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Jean-Jacques Kiladjian, Ayalew Tefferi, Francesco Passamonti, Alessandro Vannucchi, Moshe Talpaz, Francisco Cervantes, Claire N. Harrison, Ruben A. Mesa, John Mascarenhas, Nicolaas Schaap, Srdan Verstovsek, Timothy Devos, Shelonitda Rose, Jun Zhang, Oumar Sy, Animesh Pardanani

Blood (2021) 138 (Supplement 1): 2576.

https://doi.org/10.1182/blood-2021-147618

Published: 2021

Journal Articles

Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION

Massimo Breccia, MD, Michael J. Mauro, MD, Elias Jabbour, MD, Giuseppe Saglio, MD PhD, Antonio Jiménez-Velasco, MD, Philipp D le Coutre, MD, Irene DeGutis, PharmD, Wasiulla Khan, PhD, Oumar Sy, PhD, Rene Swanink, Jorge E. Cortes, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137636

Published: 2020

Journal Articles

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Massimo Breccia, MD, Jorge E. Cortes, MD, Neil P Shah, MD PhD, Giuseppe Saglio, MD, Antonio Jiménez-Velasco, MD, Philipp Le Coutre, MD, Alexander Brun, PharmD, Irene DeGutis, Sai Bathena, Oumar Sy, PhD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 4155.

https://doi.org/10.1182/blood-2019-121872

Published: 2019

Journal Articles

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Jorge E. Cortes, MD, Qian Jiang, MD, Jianxiang Wang, MD, Jianyu Weng, MD, Huanling Zhu, MD, Liu Xiaoli, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Jerald Radich, MD, Michael R. Savona, MD, Patricia Martin Regueira, MD, Oumar Sy, PhD, Renuka Gurnani, BA, Giuseppe Saglio

Blood (2018) 132 (Supplement 1): 788.

https://doi.org/10.1182/blood-2018-99-111978

Published: 2018

Journal Articles

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, MD PhD, Antonio Jiménez-Velasco, MD, Sarah Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Yair Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin Regueira, MD, Jeffrey H. Lipton, MD PhD

Blood (2018) 132 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2018-99-116563

Published: 2018

Journal Articles

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study

Sundar Jagannath, MD, Jesus G. Berdeja, MD, Robert M Rifkin, MD, Craig E. Cole, MD, Michael Alan Thompson, MD PhD, Ravi Vij, MBBS, Mihaela Popa-McKiver, PhD, Rao Saleem, Oumar Sy, PhD, William Bensinger, MD

Blood (2018) 132 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2018-99-112077

Published: 2018

Journal Articles

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Jonathon B. Cohen, MDMS, John Kuruvilla, MD, Andreas Engert, MD, Stephen M. Ansell, MD PhD, Anas Younes, MD, Hun Ju Lee, MD, Marek Trněný, Kerry J Savage, BSc, MD MSc, Radhakrishnan Ramchandren, MD, Graham P. Collins, MB BS DPhil, Pier Luigi Zinzani, MD, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Armando Santoro, MD, John M. Timmerman, MD, Mariana Sacchi, MD, Oumar Sy, PhD, Philippe Armand, MD PhD

Blood (2018) 132 (Supplement 1): 2932.

https://doi.org/10.1182/blood-2018-99-114502

Published: 2018

Journal Articles

Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study

Jonathon B Cohen, MDMS, Andreas Engert, MD, Stephen M Ansell, MD PhD, Anas Younes, MD, Marek Trneny, MD, Kerry J Savage, BSc, MD MSc, Radhakrishnan Ramchandren, MD, Graham Collins, MD PhD, Michelle A. Fanale, MD, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Armando Santoro, MD, John M Timmerman, MD, Mariana Sacchi, Oumar Sy, PhD, John Kuruvilla, MD

Blood (2017) 130 (Supplement 1): 650.

https://doi.org/10.1182/blood.V130.Suppl_1.650.650

Published: 2017

Journal Articles

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, PhD, Antonio Jiménez-Velasco, MD, Sarah M Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin-Regueira, MD, Jeffrey H. Lipton, PhD MD FRCPC

Blood (2017) 130 (Supplement 1): 314.

https://doi.org/10.1182/blood.V130.Suppl_1.314.314

Published: 2017

NARROW

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study

Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only